SMALL LYMPHOCYTIC LYMPHOMA

This study tests whether giving two pneumonia vaccines (PCV20 and PPSV23) in a series can help people with chronic lymphocytic leukemia (CLL) build a stronger immune defense against pneumococcal infections. About 61 participants with CLL who have not had treatment or are on a spe…

This study tests whether adding obinutuzumab to acalabrutinib works better than acalabrutinib alone for people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are at high risk of their disease getting worse. About 120 adults will receiv…

This study tests whether adding the drug epcoritamab after standard treatment can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. About 22 adults who have already received at least 12 months of a BTK inhibitor (a…

This study tests a combination of three drugs (acalabrutinib, venetoclax, and durvalumab) in people with Richter transformation, a rare and fast-growing lymphoma that can develop from chronic lymphocytic leukemia (CLL). The goal is to see if this treatment can improve survival by…

This study tests whether the drug mosunetuzumab, given alone or with a BTK inhibitor (like ibrutinib), can clear tiny amounts of leftover leukemia cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 40 adults who are already on or ha…

This early-phase study tests whether a patient's own immune cells, modified to target a protein called CD19 on cancer cells, can safely treat several types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. About 36 adults with relapsed or refrac…

This study is testing a new drug called AZD0486, either by itself or with other cancer treatments, in people with certain types of blood cancers like chronic lymphocytic leukemia and lymphoma. The main goals are to check if the drug is safe and to find the best dose. About 408 pa…

This study tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas. Participants must have tried at least two prior treatments without success or had side effects. The main goals ar…

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this fixed-duration therapy can effectively control the disease with…

This study tests a new drug called BGB-16673 in 150 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or stopped responding to previous BTK inhibitor pills. Participants are randomly assigned to get BGB-16673 or one of two s…

This study tests a new drug called APG-2575 in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to other treatments. About 75 adults will take the drug alone to see if it shrinks tumors and how safe it is. The goal is to …

This early-phase study tests azer-cel, a ready-made CAR T cell therapy, in adults with non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to check safety and how well the therapy works. About 135 particip…

This study tests two drug combinations (acalabrutinib plus venetoclax or obinutuzumab) in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if these combinations can shrink tumors and achieve very low levels of cancer cells…

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests whether combining two targeted drugs, pirtobrutinib and venetoclax, can eliminate cancer cells in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease got worse despite taking standard BTK inhibitors. About 30 adults wh…

This study tests whether a faster dose increase of the drug sonrotoclax, given with other medicines, is safe for people with certain blood cancers (CLL, SLL, or mantle cell lymphoma). The cancers may be new, returned, or not responding to treatment. The goal is to see if this qui…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests a new drug, sonrotoclax, combined with antibody therapy for adults with relapsed or hard-to-treat chronic lymphocytic leukemia or small lymphocytic lymphoma. About 630 participants will be randomly assigned to receive either the new combination or a standard trea…

This study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 1,200 participants will be randomly assigned to receive either nemtabrutinib or the …

This study tests three different doses of an experimental drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond to a previous type of targeted therapy (a BTK inhibitor). The goal is…

This study is for people newly diagnosed with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not yet have symptoms. It compares starting treatment early with two drugs (venetoclax and obinutuzumab) versus waiting to treat until symptoms ap…

This study tests a new drug, BGB-16673, against another drug, pirtobrutinib, in people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to prior treatment. About 500 participants will receive one of the two drugs to see which wor…

This study tests a treatment called anti-CD19 CAR T-cell therapy for people with advanced B-cell leukemias or lymphomas that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the …

This phase 3 study compares a new drug, pirtobrutinib, to the standard drug ibrutinib in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 662 participants, who may or may not have had prior treatment, will receive one of the two drugs. The goal is to …

This study tests an experimental drug, BGB-16673, designed to destroy a protein that helps certain blood cancers grow. It is for people with B-cell cancers like lymphoma or leukemia that have come back or not responded to other treatments. The trial has two parts: first finding a…

This study is for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a BTKi pill (like ibrutinib). It compares staying on the BTKi pill alone versus adding a second pill, venetoclax, for one year and then stopping both. The g…

This study tests a mix of three drugs (venetoclax, obinutuzumab, and possibly acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatment. The approach is personalized: treatment is a…

This early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…

This study tests whether taking the targeted therapy venetoclax in cycles (on and off) works as well as taking it every day, when combined with another drug, acalabrutinib, in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).…

This study tests whether adding a newer drug, epcoritamab, to a standard two-drug combination can make cancer disappear more completely and for longer in people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 33 adults who have not had…

This study tests whether giving two drugs (acalabrutinib and obinutuzumab) in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for a while. About 60 adults with untreated CLL who need therapy will participate. The goal is to see if this a…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This study offers ongoing access to the drug ibrutinib for up to 700 people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. The goal is to track long-term safety and see how well the drug controls th…

This study looks at different ways to give the drug ibrutinib to people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Some participants will also get another drug called venetoclax. The goal is to see if lowering the dose early or changing it based on…

This study tests whether giving yearly pneumococcal vaccines to people with chronic lymphocytic leukemia (CLL) offers better protection than the current standard of revaccination every 5 years. About 80 untreated CLL patients will receive either the yearly schedule or the standar…

This study follows up to 1,000 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, or related conditions to learn how these diseases progress over time. Participants receive no treatment as part of the study; instead, t…

This study looks at the costs and benefits of starting treatment early versus waiting in people with high-risk chronic lymphocytic leukemia (CLL) who have no symptoms. Researchers will track medical visits, tests, and hospital stays over 10 years to see which approach gives bette…

This study looks at whether CAR-T cell therapy reduces the protection that vaccines (like measles, mumps, and rubella) provide in people with multiple myeloma and non-Hodgkin lymphoma. Researchers will measure antibody levels before and after CAR-T treatment in 45 adults. The goa…